Gynecological disease
Conditions
Interventions
Experimental group :2 mg oliceridine intravenously
Control group:10 ug sufentanil intravenously
Sponsors
Ziyang Central Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients undergoing elective hysteroscopic surgery; 2. ASA I-II; 3. Patients aged 18-65 years; 4. BMI in 18.5-24kg/m2.
Exclusion criteria
Exclusion criteria: 1. Patients with symptoms of nausea and vomiting or using antiemetic drugs before surgery; 2. Patients with known or suspected gastrointestinal obstruction; 3. Patients with severe hepatic impairment; 4. Patients with epilepsy; 5. Patients allergic to this product; 6. Patients who cannot communicate verbally and in writing; 7. Patients who refuse to participate in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| incidence of postoperative nausea and vomiting at 0-24 h; | — |
Secondary
| Measure | Time frame |
|---|---|
| incidence of postoperative nausea and vomiting;Score of nausea ;Complete remission rate;rescue antiemetic use;the amount of intraoperative vasoactive drugs used;the incidence of adverse effects at 24 h after surgery;blood pressure, average blood pressure, heart rate, and pulse oxygen saturation; | — |
Countries
China
Contacts
Public ContactJiaman Li
Ziyang Central Hospital
Outcome results
None listed